Skip to main content

Table 2 Prevalence of autoantibodies in 863 scleroderma patients

From: Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features

Autoantibodies Patients, n(%)
Positive for antinuclear antibodies 813 (94.2)
Antibodies highly associated with SSc or scleroderma overlap syndromes 704 (81.6)
   Anti-centromere 310 (35.9)
   Anti-topoisomerase I 260 (30.1)
   Anti-PM-Scl 42 (4.9)
   Anti-U1-RNP 41 (4.8)
   Anti-RNA polymerase 33 (3.8)
   Anti-fibrillarin 12 (1.4)
   Anti-To 2 (0.2)
   Anti-Ku 10 (1.2)
   Anti-Jo-1/-Pl-7/-OJ 4 (0.5)
   Anti-U11-RNP 1 (0.1)
Other autoantibodies  
   Anti-Ro and/or anti-La 206 (23.9)
Anti-Ro52 187 (21.7)
Anti-Ro60 59 (6.8)
Anti-La 16 (1.9)
   Anti-mitochondrial M2 41 (4.8)
   Anti-p25/p23 28 (3.2)
   Anti-NOR-90 6 (0.7)
   Anti-SL 9 (1.0)
   Anti-Sm 4 (0.5)
   Anti-Sp100 4 (0.5)
   Other (known or unknown) 363 (42.1)
Negative for all highly SSc-associated antibodies 159 (18.4)
Negative for antinuclear antibodies 50 (5.8)
Autoantibody-negative by all criteria used 38 (4.4)
  1. ANA = antinuclear antibodies; SSc = systemic sclerosis.